In collaboration with co-author Udo Rudloff, M.D., Ph.D., from NIH’s National Cancer Institute’s (NCI) Center for Cancer Research, the group evaluated the effects — including toxicity — of metarrestin in pancreatic cancer mouse models. The investigators found that it prevented the further spread of pancreatic cancer by disrupting the protein-making machinery of cancer cells, and mice treated with metarrestin lived longer than mice without treatment.
“Cancer cells are rapidly dividing and need to make more proteins than healthy cells to help carry out various activities, including the ability to spread,” Rudloff said. “Interfering with the system stalls cancer cell metastasis.”
Rudloff and his NCI group currently are working with scientists at the NCATS-led Bridging Interventional Development Gaps program to collect the pre-clinical data on metarrestin needed to further its development as a candidate drug. The scientists plan to file an Investigational New Drug (IND) application in the fall with the U.S. Food and Drug Administration (FDA). FDA IND approval is necessary before a candidate drug can be tested in patients.
NCATS conducts and supports research on the science and operation of translation — the process by which interventions to improve health are developed and implemented — to allow more treatments to get to more patients more quickly. For more information about how NCATS is improving health through smarter science, visit https://ncats.nih.gov.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Cedars-Sinai Researchers Develop Drug to Combat Pancreatic Cancer
- HOT SPOTS---Biotech Hot Spots Spread Across Map of Los Angeles
- UCLA Stakes Claim on Inaugural Innovation Day
- Kite Pharma Signs New License with NIH
- Unlikely Entrepreneur---Engineered for Success
- Scientists Explore Ketamine as Tool to Fight Depression
- Abgenix Takeover Gives Amgen Grasp of the Humanized Mouse
- NantWorks Acquires Precision Biologics